NBNicoletta Botto

Nicoletta Botto

*This is an algorithmically generated author record based on publicly available information.

Nicoletta Botto has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A novel LMNA mutation (R189W) in familial dilated cardiomyopathy: evidence for a 'hot spot' region at exon 3: a case report

    by Nicoletta Botto, Simona Vittorini, Maria Giovanna Colombo, Andrea Biagini, Umberto Paradossi, Giovanni Aquaro, Maria Grazia Andreassi

    We describe a case of a patient with idiopathic dilated cardiomyopathy and cardiac conduction abnormalities who presented a strong family history of sudden cardiac death. Genetic screening of lamin A/C gene revealed in proband the presence of a novel missense mutation (R189W), near the most prevalent lamin A/C mutation (R190W), suggesting a "hot spot" region at exon 3.


    • 1 March 2010
      • Vol. 101  (3) , 127-30

    [A novel lamin A/C mutation in a family with dilated cardiomyopathy and a strong history of sudden cardiac death].

    by Maria Grazia Andreassi, Nicoletta Botto, Simona Vittorini, Silvia Pulignani, Giovanni Aquaro, Rosa Sicari

    Diseases related to lamin A/C mutations (laminopathies) are extremely heterogeneous. The common cardiac phenotype is idiopathic dilated cardiomyopathy with atrioventricular block and/or arrhythmias. Moreover, patients with lamin A/C gene mutations are at increased risk for sudden cardiac death. Here we present a family with a strong positive history of sudden cardiac death in presence of idiopathic dilated cardiomyopathy and cardiac conduction abnormalities, related to a novel lamin A/C mutation in exon 3.

    • 4 September 2009
      • Vol. 100, 356-60

    [Patent foramen ovale: "les liaisons dangereuses" between anatomy and genetics].

    by Nicoletta Botto, Lamia Ait-Ali, Rosa Sicari, Isabella Spadoni, Maria Grazia Andreassi

    We reported a case of two 24-year-old and 17-year-old male patients with episode of transient ischemic attacks and diagnosed as having patent foramen ovale (PFO). One patient had heterozygosity for the factor V Leiden mutation, and one other had heterozygosity for prothrombin G20210A mutation. Both of them were also carriers for MTHFR 677T genotype with elevated plasma levels of homocysteine (22.3 +/- 3.9 micromol/L). These findings strongly confirm and emphasize the importance of the genetic screening for thrombotic mutations in young patients with PFO-related ischemic events in order to improve secondary prevention strategies.

  • Open Access

    Clinical utility of genetic tests for inherited hypertrophic and dilated cardiomyopathies

    by Maria Giovanna Colombo, Nicoletta Botto, Simona Vittorini, Umberto Paradossi, Maria Grazia Andreassi

    Genetic testing has become an increasingly important part of medical practice for heritable form of cardiomyopathies. Hypertrophic cardiomyopathy and about 50% of idiopathic dilatative cardiomyopathy are familial diseases, with an autosomal dominant pattern of inheritance.


  • An increased platelet–leukocytes interaction at the culprit site of coronary artery occlusion in acute myocardial infarction: A pathogenic role for “no-reflow” phenomenon?

    by Nicoletta Botto, Silverio Sbrana, Giuseppe Trianni, Maria Grazia Andreassi, Marcello Ravani, Antonio Rizza, Anees Al-Jabri, Cataldo Palmieri, Sergio Berti


  • Detection of mtDNA with 4977 bp deletion in blood cells and atherosclerotic lesions of patients with coronary artery disease

    by Nicoletta Botto, Sergio Berti, Samantha Manfredi, Anees Al-Jabri, Chiara Federici, Aldo Clerico, Enrica Ciofini, Andrea Biagini, Maria Grazia Andreassi


  • Genetic polymorphisms in folate and homocysteine metabolism as risk factors for DNA damage

    by Nicoletta Botto, Maria Grazia Andreassi, Samantha Manfredi, Serena Masetti, Franca Cocci, Maria Giovanna Colombo, Simona Storti, Antonio Rizza, Andrea Biagini

    Epidemiological studies indicated a role for polymorphisms in genes of folate and homocysteine (Hcy) metabolism in the etiology of neurodegenerative disease, congenital defects and coronary artery disease (CAD). This study investigated the effect of several polymorphisms [C677 T, A1298C of methylenetetrahydrofolate reductase (MTHFR) and A66G of methionine synthase reductase (MTRR) genes] on Hcy levels and DNA damage in 68 patients who underwent coronary angiography. Plasma Hcy concentrations were higher in patients with multivessel disease with respect to monovessel disease and no-CAD patients (19.42.6 vs 11.61.2 and 13.71.4 mol/l, respectively; P=0.03). 677TT patients had higher Hcy levels than those with 677CC or 677CT genotypes (26.24.3 vs 13.11.4 and 13.01.4 mol/l, respectively; P=0.0006). No significant associations were found between A1298C and A66G polymorphisms and plasma Hcy levels. Among patients with 677CC genotype, 66GG individuals tended to have higher levels of Hcy than 66AA homozygotes (14.51.9 vs 8.90.7 mol/l, P=0.06). Multivessel disease patients showed an increased frequency of DNA damage, measured by the micronucleus (MN) frequency, as compared to monovessel disease and no-CAD subjects (12.51.1 vs 8.50.8 and 8.20.9, respectively; P=0.006). The MN were positively correlated with Hcy levels (r=0.33, P=0.006) and were significantly higher in subjects with the 677TT genotype compared with the 677CC or 677CT genotypes (14.42.0 vs 8.81.2 and 9.50.7, respectively; P=0.006). A1298C and A66G polymorphisms had no effect on MN frequency. However, among 677TT patients, 66GG subjects tended to have higher levels of MN than those 66AG and 66AA (18.23.6 vs 13.84.0 and 10.31.7, respectively; P=NS). Our results indicate that genetic instability may be associated with increased risk for multiple Hcy-related diseases.


  • Elevated levels of oxidative DNA damage in patients with coronary artery disease

    by Nicoletta Botto, Serena Masetti, Lucia Petrozzi, Cristina Vassalle, Samantha Manfredi, Andrea Biagini, Maria Grazia Andreassi

    Somatic DNA damage has been suggested to contribute to the pathogenesis of atherosclerosis. However, little is known about the role of oxidative DNA damage in patients with coronary artery disease (CAD). In this study, we used the comet assay to measure oxidative DNA damage (DNA strand breaks and enzyme-sensitive sites) in peripheral blood lymphocytes from 13 patients with angiographically documented CAD and 11 age- and sex-matched control participants. Mean values of DNA strand breaks, oxidized pyrimidines and altered purines were significantly higher in CAD patients than in the control group (11.9 ± 1.4, 18.0 ± 2.7 and 18.1 ± 3.1 compared with 3.3 ± 0.2, 2.7 ± 0.5 and 4.5 ± 1.1; P < 0.0001, P < 0.0001 and P = 0.0009, respectively). Moreover, oxidized purines (for example, 8-oxo-guanine) increased with the number of affected vessels and positively correlated with the extent of CAD measured by means of the number of the coronary lesions (r = 0.76, P = 0.003) and the Duke scoring system (r = 0.66, P = 0.01). Diabetic patients showed higher levels of oxidized pyrimidines (31.3 ± 5.5 compared with 14.1 ± 2.7; P = 0.013), while patients with dyslipidemia had elevated altered purines compared with normal patients (20.4 ± 2.6 compared with 4.9 ± 3.1; P = 0.03). These data indicate an overall elevation of oxidative DNA damage in CAD patients correlated with the severity of the disease and some atherogenic risk factors, suggesting a possible role of oxidative genetic damage in the pathogenesis of atherosclerosis.


  • Evidences for DNA damage in patients with coronary artery disease

    by Nicoletta Botto, Maria G. Andreassi, Antonio Rizza, Maria G. Colombo, Samantha Manfredi, Serena Masetti, Aldo Clerico, Fabrizio Paoli, Cataldo Palmieri, Andrea Biagini

    Several studies suggest that cancer, hypertension and atherosclerosis may share common biological mechanisms. Although an increase in the mutation rate may be involved in the pathogenesis of some cardiovascular disease, its presence in patients (pts) with coronary artery disease (CAD) has not yet studied. Aim of this study was to investigate the presence of chromosomal damage in peripheral blood lymphocytes in pts with CAD by using micronucleus (MN) test, a reliable biomarker in genetic and cancer risk assessment. In the present study were included 53 pts with angiographically documented CAD (Group I) were included; 10 pts with valvular heart disease in absence of atherosclerotic lesions of the coronary arteries (Group II); furthermore 16 healthy subjects, age and sex-matched (Group III) were included as controls. For each subject, two separate cultures of whole blood were incubated for 72 hours and harvested after a treatment with cytochalasin B (6 μg/ml) to block the cytokinesis of the lymphocytes. 1000 binucleated cells were scored for the evaluation of MN frequency. Means (±SEM) of MN frequency were 11.9±1.7, 5.9±1.2 and 3.6±0.7 in group I, II, and III respectively. The MN frequency of group I was significantly higher than that of the group III (p=0.02). Moreover, MN frequency increases with affected vessel number (6.3±0.7, 13.9±1.6, 14.9±5.3 for one-, two-, and three-vessel disease, respectively). ANOVA analysis showed that the MN frequency was significantly higher in two-vessel compared with one-vessel disease (p=0.0077). Multiple regression analysis also showed that the Duke score, which indicates the severity of CAD, and systolic blood pressure appeared to be the two determinant factors in determining MN frequency (R=0.310, p=0.01; R=0.267, p=0.03, respectively). These results suggest that CAD in humans is a condition characterized by an increase of DNA damage, which positively correlates with the increased systolic blood pressure and the severity of the atherosclerotic disease.